NFE2L2 and neoplasm: Similarly, in NSCLC, the activation of the Keap1–Nrf2 signaling pathway can comprehensively improve the resistance of tumor cells to radiotherapy, chemotherapy, and TKIs, and is significantly associated with a shorter overall survival in patients (Dempke and Reck, 2021).